— Achieve Life Sciences (NASDAQ: ACHV) reported Q4 2019 net loss of $3.2 million, or $0.30 per share, compared to a loss of $3.6 million, or $0.55 per share, last year.
— Total operating expenses were $3.2 million.
— At December 31, 2019, cash, cash equivalents and restricted cash was $16.7 million.
— Achieve Life Sciences completed a meeting with the US FDA to finalize the Phase 3 cytisinicline clinical development program.
— The company established an agreement with the FreeMind Group to assist in securing non-dilutive funding to evaluate cytisinicline in vapers and e-cigarette users.
— The company closed an underwritten public offering for gross proceeds of $13.8 million, before underwriting discounts and commissions and offering expenses.
— ACHV shares were up 12.7% in premarket hours on Friday.
Get access to timely and accurate verbatim transcripts that are published within hours of the event.
Most Popular
Docusign (DOCU) Earnings: 3Q26 Key Numbers
Docusign, Inc. (NASDAQ: DOCU) reported its earnings results for the third quarter of 2026. Revenue increased 8% year-over-year to $818.4 million. GAAP net income was $83.7 million, or $0.40
Infographic: How Ulta Beauty (ULTA) performed in Q3 2025
Ulta Beauty, Inc. (NASDAQ: ULTA) reported its earnings results for the third quarter of 2025. Net sales increased 12.9% year-over-year to $2.9 billion, driven by comparable sales growth, the Space
Hewlett Packard Enterprise (HPE) Earnings: 4Q25 Key Numbers
Hewlett Packard Enterprise (NYSE: HPE) reported revenue of $9.7 billion for the fourth quarter of 2025, up 14% from the prior-year period in actual dollars and in constant currency. Net
